DSY DASSAULT SYSTEMES SA

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and today announced an expansion of their partnership to bolster clinical research. This new agreement will take advantage of the , building on both organizations’ shared vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally.

The Medidata Experiences address the fragmented, standalone tools of the life sciences industry by offering AI-embedded, platform-based solutions across clinical workflows, unifying trial processes, diminishing silos, and reducing costs and delays. Combining these Experiences with Sanofi’s pharmaceutical knowledge will advance studies, amplifying the development of therapies with greater precision and impact.

“Sanofi and Medidata have worked together for a decade within clinical research, including a in 2024,” said Gaelan Ritter, global head of digital clinical development, Sanofi. “With this broadened relationship, we will continue harnessing the power of AI, optimizing our clinical trials, and ultimately expediting the delivery of groundbreaking medicines.”

Sanofi will employ Medidata’s expertise and capabilities in as part of this new enterprise agreement. Medidata will also provide strategic consulting and end-to-end operational support, empowering Sanofi to further streamline research processes.

“Clinical development is complex, and biopharma companies demand a strategic partner who can help them enhance data quality, improve study design, and elevate patient care," said Lisa Moneymaker, chief strategy officer, Medidata. "Through our alliance, Sanofi can leverage our unified solutions, specifically mapped out to meet their core needs, to simplify execution and accelerate the entire clinical development process.”

To learn more about the Medidata Experiences, please visit .

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at . Listen to our latest podcast, , and follow us at @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: .

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Contact:

Medidata PR

Analyst Relations

Sanofi PR

Sandrine Guendoul |

Evan Berland |

Léo Le Bourhis |

Victor Rouault |

Timothy Gilbert |

Léa Ubaldi |



EN
23/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DASSAULT SYSTEMES SA

 PRESS RELEASE

Sanofi Deepens Partnership with Medidata to Expedite the Development o...

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and today announced an expansion of their partnership to bolster clinical research. This new agreement will take advantage of the , building on both organization...

Farid Bitari ... (+3)
  • Farid Bitari
  • Nicolas David
  • Nicolas Thorez

ODDO : No, AI will not eat incumbent software vendors... on the contra...

While market sentiment has abruptly reversed regarding the AI opportunity for software vendors, we are convinced of the potential of agentic AI in the medium term for the sector, particularly for SAP, which we believe is the best positioned and which we upgrade to Outperform. Nemetschek, Planisware and Sage also seem to offer a good risk/reward trade-off following their recent de-rating. Conversely, we are downgrading Amadeus to Neutral after the reduction in its discount vs peers.

Farid Bitari ... (+3)
  • Farid Bitari
  • Nicolas David
  • Nicolas Thorez

ODDO : Non l’IA ne dévorera pas les éditeurs historiques… au contraire...

Alors que le sentiment du marché s’est brutalement retourné concernant l’opportunité de l’IA pour les éditeurs de logiciels, nous sommes convaincus du potentiel lié à l’IA agentique à moyen terme pour le secteur, notamment pour SAP qui nous semble le mieux positionné et que nous upgradons à Surperformance (vs Neutre). Nemetschek, Planisware et Sage nous semblent également offrir un bon risk/reward suite à leur récent de-rating. A l’inverse, nous dégradons Amadeus à Neutre suite à la nette réduct...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch